HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services


DOI: https://doi.org/10.29296/25877305-2022-08-02

L. Evert(1, 2), MD; T. Potupchik(3), Сandidate of Medical Sciences; Yu. Kostyuchenko(1); O. Chudinova(2), Сandidate of Biological Sciences; E. Panicheva(3), Сandidate
of Medical Sciences
1-Federal Research Center «Krasnoyarsk Scientific Center of the Siberian Branch
of the Russian Academy of Sciences», Research Institute of Medical Problems
of the North
2-N.F. Katanov Khakass State University, Ministry of Science and Higher Education of the Russia, Abakan
3-Prof. V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry
of Health of the Russia

A review of information on the most common violations of various organs and systems in adults and children who have had a coronavirus infection has been conducted. Etiopathogenetic aspects and the main clinical manifestations of post-COVID-19 syndrome (PCS) in people of different ages are highlighted. The results of our own study are included, which showed a high incidence of disorders of the musculoskeletal and other body systems in COVID-19 convalescents. Various strategies for the treatment of bridge-like disorders are highlighted. As a pharmacological correction, the possibility of therapy using of nonsteroidal anti-inflammatory drugs; central muscle relaxants; coanalgesics: anticonvulsants and antidepressants; vitamin and mineral complexes; osteoprotectors is being considered. Therapy and prevention of PCS should include correction of functional disorders, pain control, consistent physical, psychological and social rehabilitation.

musculoskeletal system
post-COVID-19 syndrome

  1. Amelin A.V., Tarasova S.V., Ignatov Yu.D. et al. Antidepressants with different action mechanisms in the treatment of chronic daily headache. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2007; 9: 38–44 (in Russ.).
  2. Bochanova E.N., Gatskikh I.V., Potupchik T.V. et al. Comparative analysis of multivitamins for children. Problems of biological, medical and pharmaceutical chemistry. 2020; 23 (11): 10–5 (in Russ.). DOI: 10.29296/25877313-2020-11-02
  3. Buryachkovskaya L.I., Melkumyants A.M., Lomakin N.V., Antonova O.A., Ermiskin V.V. Injury of vascular endothelium and erythrocytes in COVID-19 patients. Consilium Medicum. 2021; 23 (6): 469–76 (in Russ.). DOI: 10.26442/20751753.2021.6.200939
  4. Voznesenskaya T.G. Chronic pain and depression. Pharmateca. 2008; 6 (160): 105 (in Russ.).
  5. Godzenko A.A., Badokin V.V. Local therapy of myofascial pain syndrome. RMJ. Rheumatology. 2007; 26: 1998–2003 (in Russ.).
  6. Golovanova V.A., Parfenov V.A. Treatment of musculoskeletal pain during covid-19 pandemics. Clinical pharmacology and therapy. 2022; 31 (1): 24–31 (in Russ.). DOI: 10.32756/0869-5490-2022-1-24-31
  7. State Register of medicinal products [Electronic resource]. Access mode: https://grls.rosminzdrav.ru/ (in Russ.).
  8. Danilov A.B. Pain therapy. Diagnosis and treatment of fibromyalgia. Effective pharmacotherapy. Neurology. 2010; 5: 6–12 (in Russ.).
  9. Dedov D. New coronavirus infection: clinical and pathogenetic aspects, prevention, importance of vitamins and trace elements. Vrach. 2022; 33 (2): 47–9. DOI: 10.29296/25877305-2022-02-07
  10. Dedov D.V., Marchenko S.D. Vitamins, iron, zinc, selenium, selenium-containing drugs in the complex prevention of complications and treatment of patients with COVID-19. Pharmacy. 2022; 71 (1): 5–9. DOI 10.29296/25419218-2022-01-01
  11. Ekusheva E.V. Lamotrigine in treatment of chronic pain syndromes. Medical alphabet. 2020; 22: 5–8 (in Russ.). DOI: 10.33667/2078-5631-2020-22-5-8
  12. Yershov V.E., Krivova A.V., Zakharov V.P. et al. Experience of using a systemic glucocorticosteroid as an initial therapy for post-COVID-19 arthritis in outpatient practice. Russian Medical Inquiry. 2021; 5 (5): 252–6 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-252-256
  13. Igisheva L.N. Nonsteroidal anti-inflammatory drugs in the clinical practice of a pediatrician. Mother and child in Kuzbass. 2006; 3 (26): 9–13 (in Russ.).
  14. Karateev A.E. Simple analgesic paracetamol. RMJ. 2010; 9: 581 (in Russ.).
  15. Karateev A.E., Amirdzhanova V.N., Nasonov E.L. et al. “Post-COVID syndrome”: The focus is on musculoskeletal pain. Rheumatology Science and Practice. 2021; 59 (3): 255–62 (in Russ.). DOI: 10.47360/1995-4484-2021-255-262
  16. The best vitamins for teenagers [Electronic resource]. Access mode: https://www.rigla.ru/about/news/2020/vitaminy-podrostkam (in Russ.).
  17. Mikhno L., Levshin I., Polikarpochkin A. et al. Use of pharmacological agents to preserve, restore, and improve the performance of young hockey players. Vrach. 2018; 29 (9): 67–71. (in Russ.). DOI: 10.29296/25877305-2018-09-16
  18. Nasonov E.L. Coronavirus disease 2019 (covid-19): a rheumatologist’s thoughts. Rheumatology Science and Practice. 2020; 58 (2): 123–32 (in Russ.). DOI: 10.14412/1995-4484-2020-123-132
  19. Ovsyannikova E.M., Korovina N.A. Questions of optimal choice of NSAIDs in pediatric practice. Meditsinskiy sovet = Medical Council. 2014; 6: 35–9 (in Russ.). DOI: 10.21518/2079-701X-2014-6-35-39
  20. Orthomol tendo – tendon health at any age [Electronic resource]. Access mode: https://www.lsgeotar.ru/ortomol-tendo-18195.html (in Russ.).
  21. Parfenov V.A. Low back pain: causes, diagnosis, and treatment. Neurology, Neuropsychiatry, Psychosomatics. 2009; 1 (1): 19–22 (in Russ.). DOI: 10.14412/2074-2711-2009-17
  22. Savustyanenko A.V. Carbamazepine use for neuropathic pain treatment: review of studies. International Neurological Journal. 2011; 2 (40):107–15 (in Russ.).
  23. Candan S.A., Elibol N., Abdullahi A. Consideration of prevention and management of long-term consequences of post-acute respiratory distress syndrome in patients with COVID-19. Physiother Theory Pract. 2020; 36 (6): 663–8. DOI: 10.1080/09593985.2020.1766181
  24. Capaccione K.M., Yang H., West E. et al. Pathophysiology and imaging findings of COVID-19 infection: An organ-system based review. Acad Radiol. 2021; 28 (5): 595–607. DOI: 10.1016/j.acra.2021.01.022
  25. Carfi A., Bernabei R., Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020; 324 (6): 603–5. DOI: 10.1001/jama.2020.12603
  26. Darif D., Hammi I., Kihel A. et al. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb Pathog. 2021; 18 (153): 104799. DOI: 10.1016/j.micpath.2021.104799
  27. De Giorgio M.R., Di Noia S., Morciano C. et al. The impact of SARS-CoV-2 on skeletal muscles. Acta Myol. 2020; 39 (4): 307–12. DOI: 10.36185/2532-1900-034
  28. Demeco A., Marotta N., Barletta M. et al. Rehabilitation of patients post-COVID-19 infection: A literature review. J Int Med Res. 2020; 48 (8): 300060520948382. DOI: 10.1177/0300060520948382
  29. Dworkin R.H., O’Connor A.B., Audette J. Recommendation for the pharmacological management of neuropathic pain: an overwiew and literature update. Mayo Clin Proc. 2010; 85 (3): 3–14. DOI: 10.4065/mcp.2009.0649
  30. Dworkin R.H., О’Connor A.B., Backonja M. Pharmacologic management of neuropathic pain: evidence-based recommen dations. Pain. 2007; 132 (23): 7–51. DOI: 10.1016/j.pain.2007.08.033
  31. Galal I., Mohamed Hussein A., Amin M. et al. Determinants of persistent post-COVID-19 symptoms: Value of a novel COVID-19 symptom score. Egypt J Bronchol. 2021; 15: 10. DOI: 10.1186/s43168-020-00049-4
  32. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390 (10100): 1211–859. DOI: 10.1016/S0140-6736(17)32154-2
  33. Himmels J.P.W., Qureshi S.A., Brurberg K.G. et al. COVID-19: Long-term effects of COVID-19. Rapid review. URL: https://www.fhi.no/en/publ/2021/Long-Term-Effects-of-COVID-19
  34. Lopez-Leon S., Wegman-Ostrosky T., Perelman C. et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Res Sq. 2021: rs.3.rs-266574. DOI: 10.21203/rs.3.rs-266574/v1
  35. Marinangeli F., Giarratano A., Petrini F. Chronic pain and COVID-19: Pathophysiological, clinical and organizational issues. Minerva Anestesiol. 2021; 87 (7): 828–32. DOI: 10.23736/S0375-9393.20.15029-6
  36. Nalbandian A., Sehgal K., Gupta A. Post-acute COVID-19 syndrome. Nat Med. 2021; 27 (4): 601–15. DOI: 10.1038/s41591-021-01283-z
  37. Oronsky B., Larson C., Hammond T.C. et al. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 2021; 20: 1–9. DOI: 10.1007/s12016-021-08848-3
  38. Østergaard L. SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: Consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol Rep. 2021; 9 (3): e14726. DOI: 10.14814/phy2.14726
  39. Weng L.M., Su X., Wang X.Q. Pain symptoms in patients with coronavirus disease (COVID-19): A literature review. J Pain Res. 2021; 14: 147–59. DOI: 10.2147/JPR.S269206
  40. Wong A.Y., MacKenna B., Morton C.E. et al. Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: An OpenSAFELY cohort analysis based on two cohorts. Ann Rheum Dis. 2021; 80 (7): 943–51. DOI: 10.1136/annrheumdis-2020-219517
  41. Yang R., Dunn J.F., Su D. et al. Lamotrigine inhibits TRESK regulated by G protein coupled receptor agonist. J Neurosci. 2018; 367: 368–75. DOI: 10.1016/j.bbrc.2008.01.008
  42. Yang Y.C., Chou C.L., Kao C.L. Exercise, nutrition, and medication considerations in the light of the COVID pandemic, with specific focus on geriatric population: A literature review. J Chin Med Assoc. 2020; 83 (11): 977–80. DOI: 10.1097/JCMA.0000000000000393